ASLAN Pharmaceuticals Pte Ltd
10A Bukit Pasoh Road
Singapore
089824
Tel: +65-6222-4235
Fax: +65-6225-2419
Website: http://aslanpharma.com/
194 articles with ASLAN Pharmaceuticals Pte Ltd
-
Anyone who has dealt with inflammatory skin conditions is familiar with what seems like a near-constant itch. That could become a thing of the past if ASLAN Pharma has something to say about it.
-
ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting
5/20/2022
ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the presentation of a poster highlighting new data and insights related to neuronal itch mechanisms through eblasakimab’s targeting of IL-13Rα1 at the Society for Investigative Dermatology (SID) Annual Meeting.
-
ASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
5/18/2022
ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present a company update at the H.C. Wainwright Global Investment Conference.
-
ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation at the 2022 Society for Investigative Dermatology Annual Meeting
5/10/2022
ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract highlighting new data and insights related to neuronal itch mechanisms through eblasakimab’s targeting of IL-13Rα1 has been accepted for late-breaking poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting.
-
ASLAN Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4/27/2022
ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2022, and provided an update on recent corporate activities.
-
ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022
4/6/2022
ASLAN Pharmaceuticals today announced that Dr Carl Firth, CEO, will present at the 21st Annual Needham Virtual Healthcare Conference.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
4/1/2022
ASLAN Pharmaceuticals, announced that on March 28, 2022, it received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company is not in compliance with the US$1.00 minimum bid price requirement under the Nasdaq Listing Rules.
-
ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting
3/28/2022
ASLAN Pharmaceuticals today announced the oral presentation of data from the completed Phase 1b multiple-ascending-dose (MAD) study that established proof of concept for eblasakimab.
-
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/25/2022
ASLAN Pharmaceuticals announced financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on recent corporate activities.
-
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
-
ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting
3/18/2022
ASLAN Pharmaceuticals today announced that an abstract highlighting key efficacy and safety data from the completed Phase 1b study for eblasakimab (ASLAN004) in atopic dermatitis (AD) has been accepted for late-breaking oral presentation at the 2022 American Academy of Dermatology Annual Meeting, to be held in-person March 25-29, 2022, in Boston, Massachusetts.
-
ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer
3/15/2022
ASLAN Pharmaceuticals announced the appointment of Alex Kaoukhov, MD, as Chief Medical Officer based in ASLAN’s US office, effective immediately.
-
ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis
1/20/2022
ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has screened the first patient in its Phase 2b dose-ranging clinical study of eblasakimab in adults with moderate-to-severe atopic dermatitis (AD).
-
ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004
1/18/2022
ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will host the second episode in its series of Key Opinion Leader (KOL) events on the emerging Atopic Dermatitis (AD) landscape and ASLAN004, on Thursday, January 20, 2022, at 12:00pm ET.
-
ASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology Conferences
1/11/2022
ASLAN Pharmaceuticals announced that the results from the dose escalation portion of the completed Phase 1b Proof-of-Concept study of ASLAN004 in atopic dermatitis have been accepted for poster presentation at the 2022 Winter Clinical Dermatology Conference, to be held in Koloa, Hawaii, January 14-19, 2022.
-
ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022
1/6/2022
ASLAN Pharmaceuticals, a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced that Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright Bioconnect Conference on January 10, 2022.
-
ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration
12/6/2021
ASLAN Pharmaceuticals today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical trials.
-
ASLAN Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
11/22/2021
ASLAN Pharmaceuticals, a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced that Dr Carl Firth, CEO, will be participating in fireside chats at two upcoming virtual health conferences.
-
ASLAN Pharmaceuticals to Participate in Fireside Chat at the 12th Annual Jefferies London Healthcare Conference 2021
11/10/2021
ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in-person at the 12th Annual Jefferies London Healthcare Conference on November 17, 2021, at 1:00pm GMT.